Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Nucleic Acids Research. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q).

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) approved VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

SEPTEMBER 1, 2021

Participants are not eligible for the trial if they have received the first dose of a COVID-19 vaccine more than seven days prior to enrollment, have previously had COVID-19 or are showing any signs or symptoms of COVID-19. About Molnupiravir.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

The Pharma Data

NOVEMBER 18, 2021

As previously reported, at 48 weeks, both trials met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels ?50 All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. About Merck.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

OCTOBER 25, 2021

At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? Merck Research Laboratories. “ 50 clones/ mL, demonstrating that antiviral efficacity was similar between DOR/ ISL and ART ( ILLUMINATE SWITCH A) and between DOR/ ISL and BIC/ FTC/ TAF (ILLUMINATE SWITCH B).

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

OCTOBER 27, 2021

Joan Butterton, vice chairman, global clinical development, contagious conditions, Merck Research Laboratories. The primary endpoint is the proportion of study actors with HIV-1 RNA viral cargo ? 50 c/ mL at Week 24. Their safety and efficacity haven’t yet been established. About Merck.

Treatment 52

Treatment Clinical Trials Clinical Development Research Laboratories 52

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40